EWM
ACHN

Edge Wealth Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Edge Wealth Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-750
Closed -$6K – 538
2016
Q3 		$6K Hold
750
– – ﹤0.01% 385
2016
Q2 		$6K Hold
750
– – ﹤0.01% 360
2016
Q1 		$6K Hold
750
– – ﹤0.01% 337
2015
Q4 		$8K Hold
750
– – ﹤0.01% 316
2015
Q3 		$5K Hold
750
– – ﹤0.01% 353
2015
Q2 		$7K Hold
750
– – ﹤0.01% 325
2015
Q1 		$7K Sell
750
-750
-50% -$9.37K ﹤0.01% 326
2014
Q4 		$18K Buy
+1,500
New +$18.3K 0.01% 268
2014
Q3 		– Sell
-1,000
Closed -$8K – 436
2014
Q2 		$8K Buy
+1,000
New +$3.99K ﹤0.01% 308

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Edge Wealth Management's ACHN Position: Q4 2016 in Review

Edge Wealth Management sold out of Achillion Pharmaceuticals (ACHN) in Q4 2016, closing a stake of 750 shares — an estimated $6K sold.

Edge Wealth Management first reported a position in ACHN in Q2 2014 and held it in 9 quarters. The position peaked at $18K in Q4 2014. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

  • Edge Wealth Management reported no remaining Achillion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Edge Wealth Management sold 750 Achillion Pharmaceuticals shares in Q4 2016, an estimated $6K.
  • Edge Wealth Management first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 9 quarters.
  • Edge Wealth Management's Achillion Pharmaceuticals position peaked at $18K in Q4 2014.
  • 140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on Edge Wealth Management's 13F filing for Q4 2016, filed 24 Jan 2017.